ImmunityBio Inc (NASDAQ:IBRX) price on current trading day, fall -1.78% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.76.
A look at the stock’s price movement, the close in the last trading session was $2.81, moving within a range at $2.7 and $2.82. The beta value (5-Year monthly) was -0.183. Turning to its 52-week performance, $10.53 and $2.28 were the 52-week high and 52-week low respectively. Overall, IBRX moved -17.61% over the past month.
ImmunityBio Inc’s market cap currently stands at around $2.36 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-02.
Analysts have a consensus estimate of 17.5M for the company’s revenue for the quarter, with a low and high estimate of 13.78M and 19.74M respectively. The average forecast suggests up to a 43,644.38% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 105.24M, representing a 613.74% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IBRX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 0 recommend IBRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Sell which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IBRX’s current price about -8.35% and -9.88% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.54, while 7-day volatility ratio is 6.19% and 9.48% in the 30-day chart. Further, ImmunityBio Inc (IBRX) has a beta value of 0.44, and an average true range (ATR) of 0.26. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -117.39% off current price level while to achieve the yearly target high, price needs to move -117.39%. Nonetheless, investors will most likely welcome a -117.39% jump to $6 which is the analysts’ median price.
If we refocus on ImmunityBio Inc (NASDAQ:IBRX), historical trading data shows that trading volumes averaged 4.26 over the past 10 days and 5.95 million over the past 3 months. The company’s latest data on shares outstanding shows there are 852.74 million shares.
The 89.60% of ImmunityBio Inc’s shares are in the hands of company insiders while institutional holders own 9.90% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 60.93 million on 2025-02-28, giving us a short ratio of 9.95. The data shows that as of 2025-02-28 short interest in ImmunityBio Inc (IBRX) stood at 1914.9999999999998 of shares outstanding, with shares short rising to 55.92 million registered in 2025-01-31. Current price change has pushed the stock 7.81% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IBRX stock continues to rise going into the next quarter.
